Merck & Co., Inc. (MRK)
Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech
After years of lagging the market, healthcare may be taking on a new role in investor portfolios.
Merck & Co.: Why The Market Is Right To Start Buying Into Post-Keytruda Promise
Merck & Co., Inc. has rebounded 55% in the past year, driven by optimism around its post-Keytruda strategy despite looming patent expiry in 2028. MRK has aggressively pursued acquisitions and partnerships, notably with Terns Pharma, Cidara, Verona, and Daiichi Sankyo, to diversify its pipeline. By 2030, I project MRK can offset Keytruda declines with ~$17.35bn in new product revenues, supporting a potential $350bn valuation—~15% above current levels.
Merck (MRK) Recently Broke Out Above the 20-Day Moving Average
From a technical perspective, Merck (MRK) is looking like an interesting pick, as it just reached a key level of support. MRK recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
Merck (MRK) Crossed Above the 50-Day Moving Average: What That Means for Investors
Merck (MRK) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, MRK broke out above the 50-day moving average, suggesting a short-term bullish trend.
Merck & Co., Inc. (MRK) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Merck & Co., Inc. (MRK) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Merck & Co., Inc. (MRK) Discusses Oncology Strategy and Program Update With Focus on Clinical Progress and Pipeline Diversification Transcript
Merck & Co., Inc. (MRK) Discusses Oncology Strategy and Program Update With Focus on Clinical Progress and Pipeline Diversification Transcript
Merck's Calderasib Gets FDA's Breakthrough Therapy Tag for NSCLC
MRK wins FDA Breakthrough Therapy designation for calderasib plus Keytruda for certain newly diagnosed metastatic KRAS G12C-mutant NSCLC patients.
Can MRK's New Drugs & Pipeline Aid Long-Term Growth Post Keytruda LOE?
Merck bets on newer drugs, pipeline candidates and M&A deals to offset looming Keytruda patent expiry and drive long-term growth.
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Merck chicken bronchitis vaccine approved for use in China
Merck said its vaccine against bronchitis in chickens has been approved by the Chinese agriculture ministry for use in the world's largest chicken-rearing country, which is home to over 5 billion birds.
MRK Stock Gains After CHMP Backs Keytruda Combo for Bladder Cancer
Merck jumps after CHMP backs Keytruda plus Padcev for certain bladder cancer patients, a combo with the potential to expand treatment options.
Merck stock jumps as Keytruda combo trials boost cancer pipeline
Shares of Merck & Co. (MRK) rose 5% on Friday after the pharmaceutical giant reported positive developments across multiple oncology programs, reinforcing investor confidence in its efforts to extend the dominance of blockbuster cancer drug Keytruda ahead of looming patent expirations later this decade. The rally followed encouraging Phase 3 clinical trial results involving sacituzumab tirumotecan, or sac-TMT, an antibody-drug conjugate developed in partnership with Sichuan Kelun-Biotech Biopharmaceutical.
